Bifidobacterium animalis and application of compound bacterium preparation prepared from Bifidobacterium animalis in preparing medicine for treating or preventing avian influenza virus infection
US11786566B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Jan 4, 2021 |
| Grant date | Oct 17, 2023 |
| Priority date | — |
| Expiry date | May 24, 2041 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P31/16
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Bifidobacterium animalis and application of a compound bacterium preparation prepared from the Bifidobacterium animalis in the preparation of a medicine for treating or preventing avian influenza virus infection. The invention discovers that Bifidobacterium animalis ATCC Accession No. 25527 can be used for treating animals infected by H7N9, and after the Bifidobacterium animalis ATCC Accession No. 25527 is compounded with Bifidobacterium pseudolongum ATCC Accession No. 25526, the effect is better. The compound preparation can regulate the body immune response, remarkably improve the weight loss and lung tissue injury caused by H7N9 influenza virus infection, and obviously improve the survival rate of mice infected by H7N9 influenza virus. The compound probiotic preparation provided by the invention has a remarkable effect of resisting H7N9 influenza virus infection, and can be effectively used for preventing and treating avian influenza virus infection.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.